Diligence memo · auto-generated · as of July 2, 2026
Clementia Pharmaceuticals Inc.
Clementia Pharmaceuticals Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Clementia Pharmaceuticals Inc. operates in Pharmaceuticals, based in DORVAL.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Clementia Pharmaceuticals Inc. has raised $60M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $60M on 2015-06-22.
Most recent recorded round closed around 2015-06-22.
Valuation (modeled)modeled
Provath models Clementia Pharmaceuticals Inc. at approximately $2.1B (range $195M–$5.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.02× the median modeled value of Series C Pharmaceuticals companies in 2013–2015 (19 peers) — value vs value, same stage and era. Within the normal band (102% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 11.0 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 84% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 94% of those peers.
Closest niche peers: Bellicum Pharmaceuticals, Inc, Paratek Pharmaceuticals Inc, Turing Pharmaceuticals AG, Seres Health, Inc., Syndax Pharmaceuticals Inc.
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.